Wendell Conyers

Wendell Conyers serves as a Contract Officer responsible for managing complex procurements within the life sciences and biotechnology sectors. In this role, he ensures compliance with federal acquisition regulations while advancing mission-critical research and manufacturing capabilities. His portfolio centers on high-value, technically sophisticated acquisitions involving pharmaceutical and biological product development, as well as applied research in life sciences. Conyers plays a pivotal role in executing full lifecycle contracting activities—from market research and solicitation development to award administration and contract closeout—ensuring timely delivery of essential scientific and medical capabilities. While no specific contractor relationships are currently identifiable in the data, Conyers routinely engages with a diverse range of vendors, including large prime contractors with established GSA schedules and specialized small businesses capable of meeting stringent regulatory and quality control requirements. His procurement approach emphasizes performance-based outcomes and technical capability over cost alone, fostering partnerships with firms possessing validated GMP, cGMP, and FDA-compliant manufacturing or R&D infrastructure. Conyers maintains a strong preference for unrestricted competitions, with 100% of his acquisitions issued without set-aside designations. This reflects a strategic focus on maximizing competition among qualified entities with proven technical expertise, rather than socioeconomic categorization. While he does not prioritize 8(a), HUBZone, or SDVOSB set-asides, his process remains fully compliant with all small business participation goals and encourages broad market engagement. His primary procurement focus lies in NAICS 325412 (Pharmaceutical Preparation Manufacturing) and 325414 (Biological Product Manufacturing), complemented by equal emphasis on R&D services under NAICS 541714 and 541712. He regularly procures GMP-compliant drug formulations, biologics production systems, preclinical research services, and analytical development solutions, demonstrating deep familiarity with FDA-regulated environments and translational science workflows.